(Reuters) – Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the health technology company at about $2.57 billion at the top end.
Catalent’s IPO of 42.5 million shares is expected to raise about $935 million at the top end of the expected price range.
The company provides advanced delivery technologies for drugs, biologics and consumer health products.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.